Advances In™ Amyotrophic Lateral Sclerosis — Developments in SOD1 Targeting

Release Date: August 31, 2020
Expiration Date: August 31, 2021

Activity Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of patients with amyotrophic lateral sclerosis (ALS) with a superoxide dismutase 1 (SOD1) mutation. It offers a review of current agents and a forward-looking perspective on how new and novel agents might impact clinical practice. The essentials of disease classification and molecular testing, clinical trial data, and current and emerging treatment strategies are presented in a multimedia format that includes a series of video interviews with clinical experts integrated into text-based elements.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Biogen.

Target Audience

This online educational activity is directed toward neurologists, internists, and other health care professionals (eg, primary care physicians, nurse practitioners, and physician assistants) involved in the treatment of patients with ALS.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Characterize the clinical relevance of common genetic mutations involved in the etiology of ALS
• Discuss the mechanism of action and clinical trial results of antisense oligonucleotides that target SOD1 mutations
• Assess patient eligibility for ongoing lung cancer clinical trials and treatment regimens under investigation

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Jinsy A. Andrews, MD, MSc, FAAN
Director of Neuromuscular Clinical Trials
Columbia University Irving Medical Center
New York, NY
Associate Professor of Neurology
Department of Neurology
Columbia University
New York, NY

Disclosures:Grant Research Support: Neuraltus Pharmaceuticals Inc, F. Hoffman-La Roche Inc, Biogen, and Orion Corp; Consultant: ALS Biopharma LLC, AveXis Inc, Biogen, and Cytokinetics Inc.

Terry D. Heiman-Patterson, MD
Professor of Neurology
Director MDA ALS Center of Hope
Department of Neurology
Lewis Katz School of Medicine at Temple University
Philadelphia, PA

Disclosures:Grant Research Support: Amylyx Pharmaceuticals Inc, Cytokinetics Inc, Mitsubishi Tanabe Pharma America Inc, and Orion Corp; Consultant: Biohaven Pharmaceuticals Inc, Cytokinetics Inc, ITF Pharma Inc, Samus Therapeutics, and Mitsubishi Tanabe Pharma America Inc.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.